WO2024042077A1 - Procédé de prédiction de la réponse à un inhibiteur de l'activité de la kinase egfr - Google Patents
Procédé de prédiction de la réponse à un inhibiteur de l'activité de la kinase egfr Download PDFInfo
- Publication number
- WO2024042077A1 WO2024042077A1 PCT/EP2023/073029 EP2023073029W WO2024042077A1 WO 2024042077 A1 WO2024042077 A1 WO 2024042077A1 EP 2023073029 W EP2023073029 W EP 2023073029W WO 2024042077 A1 WO2024042077 A1 WO 2024042077A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- egfr
- phosphorylation
- subject
- level
- residue
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 68
- 230000000694 effects Effects 0.000 title claims abstract description 63
- 239000003112 inhibitor Substances 0.000 title claims abstract description 35
- 230000004044 response Effects 0.000 title claims abstract description 28
- 108060006698 EGF receptor Proteins 0.000 title description 154
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims abstract description 16
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims abstract description 9
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims abstract 15
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims abstract 5
- 230000026731 phosphorylation Effects 0.000 claims description 120
- 238000006366 phosphorylation reaction Methods 0.000 claims description 120
- 206010028980 Neoplasm Diseases 0.000 claims description 51
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 48
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 48
- 230000035772 mutation Effects 0.000 claims description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
- 201000010099 disease Diseases 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 13
- 108091000080 Phosphotransferase Proteins 0.000 claims description 12
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 12
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 12
- 102000020233 phosphotransferase Human genes 0.000 claims description 12
- 229940121647 egfr inhibitor Drugs 0.000 claims description 11
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 10
- 230000011664 signaling Effects 0.000 claims description 9
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 8
- 229960001433 erlotinib Drugs 0.000 claims description 8
- 229960002584 gefitinib Drugs 0.000 claims description 8
- 230000006916 protein interaction Effects 0.000 claims description 6
- ZGHQGWOETPXKLY-XVNBXDOJSA-N chembl77030 Chemical compound NC(=S)C(\C#N)=C\C1=CC=C(O)C(O)=C1 ZGHQGWOETPXKLY-XVNBXDOJSA-N 0.000 claims description 5
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 5
- 229960001972 panitumumab Drugs 0.000 claims description 5
- YZOFLYUAQDJWKV-UHFFFAOYSA-N 2-[(3,4,5-trihydroxyphenyl)methylidene]propanedinitrile Chemical compound OC1=CC(C=C(C#N)C#N)=CC(O)=C1O YZOFLYUAQDJWKV-UHFFFAOYSA-N 0.000 claims description 4
- VTJXFTPMFYAJJU-UHFFFAOYSA-N 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile Chemical compound OC1=CC=C(C=C(C#N)C#N)C=C1O VTJXFTPMFYAJJU-UHFFFAOYSA-N 0.000 claims description 4
- ULTTYPMRMMDONC-UHFFFAOYSA-N 5-[(2,5-dihydroxyphenyl)methyl-[(2-hydroxyphenyl)methyl]amino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2C(=CC=CC=2)O)CC=2C(=CC=C(O)C=2)O)=C1 ULTTYPMRMMDONC-UHFFFAOYSA-N 0.000 claims description 4
- RTYOLBQXFXYMKY-UHFFFAOYSA-N 5-[bis[(2-hydroxyphenyl)methyl]amino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2C(=CC=CC=2)O)CC=2C(=CC=CC=2)O)=C1 RTYOLBQXFXYMKY-UHFFFAOYSA-N 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 229940084651 iressa Drugs 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 229940120982 tarceva Drugs 0.000 claims description 4
- 229960001686 afatinib Drugs 0.000 claims description 3
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 3
- 229960005395 cetuximab Drugs 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- JKNOYWVMHPMBEL-UNXLUWIOSA-N (3z)-2-amino-4-(3,4,5-trihydroxyphenyl)buta-1,3-diene-1,1,3-tricarbonitrile Chemical compound N#CC(C#N)=C(N)\C(C#N)=C\C1=CC(O)=C(O)C(O)=C1 JKNOYWVMHPMBEL-UNXLUWIOSA-N 0.000 claims description 2
- USOXQZNJFMKTKJ-XVNBXDOJSA-N (e)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide Chemical compound NC(=O)C(\C#N)=C\C1=CC=C(O)C(O)=C1 USOXQZNJFMKTKJ-XVNBXDOJSA-N 0.000 claims description 2
- FTFRZXFNZVCRSK-UHFFFAOYSA-N N4-(3-chloro-4-fluorophenyl)-N6-(1-methyl-4-piperidinyl)pyrimido[5,4-d]pyrimidine-4,6-diamine Chemical group C1CN(C)CCC1NC1=NC=C(N=CN=C2NC=3C=C(Cl)C(F)=CC=3)C2=N1 FTFRZXFNZVCRSK-UHFFFAOYSA-N 0.000 claims description 2
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 claims description 2
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 claims description 2
- 229950002205 dacomitinib Drugs 0.000 claims description 2
- 229940082789 erbitux Drugs 0.000 claims description 2
- 229950008001 matuzumab Drugs 0.000 claims description 2
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 claims description 2
- UOHFCPXBKJPCAD-UHFFFAOYSA-N tyrphostin 1 Chemical compound COC1=CC=C(C=C(C#N)C#N)C=C1 UOHFCPXBKJPCAD-UHFFFAOYSA-N 0.000 claims description 2
- GFNNBHLJANVSQV-UHFFFAOYSA-N tyrphostin AG 1478 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 GFNNBHLJANVSQV-UHFFFAOYSA-N 0.000 claims description 2
- KXDONFLNGBQLTN-WUXMJOGZSA-N tyrphostin AG 825 Chemical compound COC1=CC(\C=C(/C#N)C(N)=O)=CC(CSC=2SC3=CC=CC=C3N=2)=C1O KXDONFLNGBQLTN-WUXMJOGZSA-N 0.000 claims description 2
- TUCIOBMMDDOEMM-RIYZIHGNSA-N tyrphostin B42 Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCC1=CC=CC=C1 TUCIOBMMDDOEMM-RIYZIHGNSA-N 0.000 claims description 2
- 229960000241 vandetanib Drugs 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 11
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 25
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract description 14
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract description 14
- 239000000090 biomarker Substances 0.000 abstract description 7
- 238000009007 Diagnostic Kit Methods 0.000 abstract description 2
- 102000001301 EGF receptor Human genes 0.000 description 155
- 102000004169 proteins and genes Human genes 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 41
- 239000000523 sample Substances 0.000 description 26
- 208000035475 disorder Diseases 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000019491 signal transduction Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 10
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 9
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 9
- 210000002919 epithelial cell Anatomy 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 108700024394 Exon Proteins 0.000 description 5
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 5
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 5
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 5
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 101150039808 Egfr gene Proteins 0.000 description 4
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 4
- 238000011123 anti-EGFR therapy Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 108700021358 erbB-1 Genes Proteins 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102220569924 Epidermal growth factor receptor_G719A_mutation Human genes 0.000 description 2
- 102220541683 Epidermal growth factor receptor_L858R_mutation Human genes 0.000 description 2
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 229940087158 gilotrif Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical group OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 2
- 230000009822 protein phosphorylation Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 150000003246 quinazolines Chemical class 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 229960001612 trastuzumab emtansine Drugs 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- BSPLGGCPNTZPIH-IPZCTEOASA-N (e)-n-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide;hydrate Chemical compound O.C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 BSPLGGCPNTZPIH-IPZCTEOASA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102220587428 Epidermal growth factor receptor_G719C_mutation Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940125436 dual inhibitor Drugs 0.000 description 1
- -1 e.g. Substances 0.000 description 1
- 238000001861 endoscopic biopsy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 230000008826 genomic mutation Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 102000045108 human EGFR Human genes 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 238000013275 image-guided biopsy Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000019639 protein methylation Effects 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102220005774 rs121913438 Human genes 0.000 description 1
- 102220014422 rs397517094 Human genes 0.000 description 1
- 229940125457 rybrevant Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007389 shave biopsy Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940094060 tykerb Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the invention relates to a method to select patients that may respond to a tyrosine kinase inhibitor (TKI) treatment.
- the invention further relates to a diagnostic kit for the prediction of a response to an inhibitor of EGFR kinase activity.
- the invention relates to the use of phosphorylated T59 on SHP2 as a biomarker to predict EGFR kinase activity.
- tyrosine kinases Enzymes capable of catalyzing such reactions are denoted tyrosine kinases, whereas tyrosine kinase inhibitors (TKI) are pharmaceutics that inhibit the activation of proteins by tyrosine phosphorylation.
- Growth factor receptor tyrosine kinases play a role in the etiology and progression of a variety of disorders or diseases, including, e.g., malignant diseases in humans. These receptors are anchored by means of a transmembrane domain in the membranes of cells that express them. An extracellular domain binds to the growth factor.
- the binding of the growth factor to the extracellular domain results in a signal being transmitted from the exterior of the cell to the intracellular kinase domain.
- the transduction of this signal contributes to a variety of pleiotrophic responses, which are responsible, e.g., for the induction of DNA synthesis, altered gene expression, cell growth, proliferation and differentiation, etc.
- the epidermal growth factor receptor is a tyrosine kinase receptor and a member of HER/ErbB family that consists of four members: EGFR (HER1/ErbB1), HER2/neu (ErbB2), HER3 (ErbB3) and HER4 (ErbB 4).
- the receptor consists of three parts: a glycosylated extracellular ligand-binding domain, a transmembrane domain that consists of a single chain, and an intracellular protein-tyrosine kinase domain. Ligand binding to the extracellular domain causes the receptor to dimerize and activate the protein-tyrosine kinase activity.
- EGFRs are widely distributed at the cell surface of the mammalian epithelial cells, fibroblasts, glial cells, keratinocytes, etc.
- the EGFR signaling pathway plays an important role in physiological processes like cell growth, proliferation and differentiation, etc.
- the functional deficiency of protein tyrosine kinase, like EGFR, or the abnormality in the activity or cellular localization of the key factors in the related signaling pathways may all lead to occurrence of tumors, diabetes, immune deficiencies and cardiovascular diseases.
- Several malignancies are associated with the mutation or an increased expression of members of the ErbB family.
- glioblastomas including glioblastoma multiforme
- cancers of the lung adenocarcinomas, including bronchoalveolar carcinoma (BAC) and non-small cell lung cancer (NSCLC)
- BAC bronchoalveolar carcinoma
- NSCLC non-small cell lung cancer
- Lapatinib (Tykerb®) is an orally effective quinazoline derivative which is an EGFR/HER2 dual inhibitor, used in the treatment of ErbB2- overexpressing breast cancer.
- the afore-mentioned TKI competitively bind to the phosphorylation site of the tyrosine kinase at the intracellular segment to block the interaction between the phosphorylation site and ATP and inhibit the phosphorylation of tyrosine and a series of downstream signal transduction, and then inhibit the growth of tumor cells.
- the reversible EFGR inhibitors Gefitinib and Erlotinib show favorable therapeutic effects on non-small cell lung cancer patients with EGFR mutation; they can significantly prolong the progression-free survival (PFS) and overall survival (OS) of the patients.
- Trastuzumab, Pertuzumab, Amivantamb (Rybrevant®) and Trastuzumab- Emtansine are monoclonal antibodies which are given intravenously, target the extracellular domain and are used for the treatment of ErbB2-positive breast cancer.
- Trastuzumab-Emtansine is an antibody-drug conjugate that delivers a cytotoxic drug to cells overexpressing ErbB2.
- Cetuximab and Panitumumab are monoclonal antibodies that target ErbB1 and are used in the treatment of colorectal cancer.
- W02007/106432 describes a method for predicting the response of a subject having a disease or condition mediated by EGFR (e.g., a cancer of epithelial origin, such as NSCLC) to an EGFR kinase inhibitor.
- EGFR e.g., a cancer of epithelial origin, such as NSCLC
- the amount of phosphorylation at residues Y1068 and T1148 in EGFR is measured.
- An elevated level of phosphorylation at the two residues is used as an indicator that the subject is likely to be responsive to an agent that inhibits the kinase activity of EGFR.
- this method has not become established in practice. There is currently no companion diagnostic test, wherein phosphosites on the EGFR are used to select responders for an anti tumor treatment.
- a further group of enzymes that together with the tyrosine kinases play an important role in signal transduction cascades are the protein tyrosine phosphatases (PTPs) that are capable of removing phosphate groups from phosphorylated tyrosine residues on proteins.
- PTPs protein tyrosine phosphatases
- a member of the PTP family is SHP2 (Src homology region 2 domain-containing phosphatase-2), an enzyme also known as protein tyrosine phosphatase non-receptor type 11 (also denoted as PTPN11).
- SHP2 contains two tandem Src homology-2 domains, which function as phospho-tyrosine binding domains and mediate the interaction of SHP2 with its substrates.
- SHP2 can be activated by a variety of upstream activities to mediate phospho-tryosine signal transduction in various cellular pathways (see Z.Song et.al, Acta Pharmaceutica Sinica B, 11 (1 ), 2021 , 13-29.).
- Zhang et aL Cancer Research, vol. 81 , no. 11 , 2021 , p. 3051 -3066, relates to a study of the proteome and phosphoproteome of a series of isogenic EGFR mutant lung adenocarcinoma cell lines that are either sensitive or resistant to these drugs. It was determined whether phosphorylation changes in SHP2 are associated with PI3K/AKT and MAPK signaling in TKI resistant cells. The relative quantification of phosphorylated proteins normalized to total protein expression was performed on Western blots.
- figures 4 and 5 of the present application demonstrate that neither the total phospho-threonine signal, nor the total phosphorylation signal on SHP2 function as good classifiers for EGFR activity.
- referenced antibodies could be used to measure all phospho-threonine residues of SHP2 (PTN11 ) but would have worse performance as a classifier.
- present invention defines a novel way of defining patients who have a benefit from an EGFR therapy, and does not sub-divide this group further into responders and non-responders (see fig. 6 of the present invention).
- HER3 and ERK1/2 are known signaling hubs, and phosphorylation of these is dependent on multiple input signals, and they phosphorylate many output proteins.
- they may be phosphorylated in EGFR active cells, they are also phosphorylated under many other conditions or in many other molecular states, and it would not be expected that they can form the basis of an accurate EGFR activity predictor. This is confirmed by the present invention (see fig 4 and 5 of the present). In particular, this data show that HER3 and ERK1/2 perform very poorly compared to pT59 on PTN11 .
- the method is applied to patients who have a cancer of epithelial cell origin, in particular NSCLC (nonsmall cell lung cancer).
- the method should overcome the disadvantages of the state of the art.
- Current state of the art methods are based on mutation analysis, which has its biological limitations. Over active EGFR can be caused not only by mutations, but also through other mechanisms.
- An IHC (immunohistochemical) based method would be a good alternative and allow to examine and identify more patients that could benefit from TKI treatment.
- tumor activating mutations that can be used to identify patients that respond to TKI therapy.
- EGFR mutations which are present in a subgroup of NSCLC adenocarcinoma patients (about 15%) that can be used as indicative standard of EGFR activity, and identify patients that respond to TKI treatment.
- the phosphosite used according to the invention was identified from a NSCLC tumor data set by comparison between NSCLC cases annoated with a wild-type EGFR and mutant activated EGFR. In this analysis the phosphorylation signal of phosphosites was measured through mass spectrometry. Surprisingly, the phosphorylation of the T59 amino acid on SHP2 showed the largest statistically significant effect between the two groups, and in isolation resulted a signal strong enough to clearly distinguish samples with an activated EGFR from the bulk of the cohort.
- the method according to the invention can determine an individual patient's drug sensitivity prior to treatment, optionally in conjunction with genomic analysis, and thus can serve as the basis for individualized targeted therapy.
- the phosphosite (p-site) at T59 on SHP2 can act as a biomarker.
- the method allows to identify patients with activated EGFR that would be missed by classical mutation testing.
- An immunohistochemistry based companion diagnostic may be a useful alternative in a routine laboratory or clinical setting.
- the stability of the phosphosite employed according to the invention is not influenced by the ischemia time. Stability of p-sites are sometimes limiting the practical use, however in this case ischemia time is no limiting factor for method of the invention.
- the invention relates to a method for predicting the response of a subject suffering from a disease or disorder to an inhibitor of EGFR kinase activity, comprising the steps: a) collecting a sample from a tumor of a subject that has a cancer of epithelial cell origin b) determining the level of phosphorylation of at least one phosphorylation site, comprising residue T59 in the SHP2 protein; c) comparing the level of phosphorylation of the at least one phosphorylation site, comprising residue T59, to a control level; wherein a significantly elevated level of phosphorylation of at least one phosphorylation site, comprising residue T59, compared to the control level indicates that the subject is likely to be responsive to an agent that inhibits the kinase activity of EGFR.
- the invention relates to a method for predicting the response of a subject suffering from non-small cell lung cancer (NSCLC)to an inhibitor of EGFR kinase activity, comprising the steps: a) collecting a sample from a tumor of a subject that having non-small cell lung cancer (NSCLC); b) determining the level of phosphorylation of at least one phosphorylation site, comprising residue T59 in the SHP2 protein; c) comparing the level of phosphorylation of the at least one phosphorylation site, comprising residue T59, to a control level; wherein a significantly elevated level of phosphorylation of at least one phosphorylation site, comprising residue T59, compared to the control level indicates that the subject is likely to be responsive to an agent that inhibits the kinase activity of EGFR.
- NSCLC non-small cell lung cancer
- the invention further relates to a method for selecting a subject suffering from a disease or disorder that may respond to an inhibitor of EGFR kinase activity, comprising the steps: a) collecting a sample from a tumor of a subject that has a cancer of epithelial cell origin b) determining the level of phosphorylation of at least one phosphorylation site, comprising residue T59 in the SHP2 protein; c) comparing the level of phosphorylation of the at least one phosphorylation site, comprising residue T59, to a control level; wherein a significantly elevated level of phosphorylation of at least one phosphorylation site, comprising residue T59, compared to the control level indicates that the subject is likely to be responsive to an agent that inhibits the kinase activity of EGFR.
- the invention further relates to a method for selecting a subject suffering from non-small cell lung cancer (NSCLC) that may respond to an inhibitor of EGFR kinase activity, comprising the steps: a) collecting a sample from a tumor of a subject that has non-small cell lung cancer (NSCLC); b) determining the level of phosphorylation of at least one phosphorylation site, comprising residue T59 in the SHP2 protein; c) comparing the level of phosphorylation of the at least one phosphorylation site, comprising residue T59, to a control level; wherein a significantly elevated level of phosphorylation of at least one phosphorylation site, comprising residue T59, compared to the control level indicates that the subject is likely to be responsive to an agent that inhibits the kinase activity of EGFR.
- NSCLC non-small cell lung cancer
- the invention further relates to a method for identifying over-active EGFR in a subject, comprising the steps: i) collecting a sample from a tumor of a subject having a cancer of epithelial cell origin; ii) determining the level of phosphorylation of at least one phosphorylation site comprising residue T59 in the SHP2 protein; iii) comparing the level of phosphorylation of at least one phosphorylation site comprising residue T59 to a control level; wherein a significantly elevated level of phosphorylation of at least one phosphorylation site comprising residue T59 compared to the control level indicates that the subject has likely an over-active EGFR.
- the invention further relates to a method for identifying over-active EGFR in a subject, comprising the steps: i) collecting a sample from a tumor of a subject having non-small cell lung cancer (NSCLC); ii) determining the level of phosphorylation of at least one phosphorylation site comprising residue T59 in the SHP2 protein; iii) comparing the level of phosphorylation of at least one phosphorylation site comprising residue T59 to a control level; wherein a significantly elevated level of phosphorylation of at least one phosphorylation site comprising residue T59 compared to the control level indicates that the subject has likely an over-active EGFR.
- NSCLC non-small cell lung cancer
- the invention also relates to a kit for predicting the response of a subject suffering from a disease or disorder to an inhibitor of EGFR kinase, comprising means for determining the level of phosphorylation of at least one phosphorylation site, comprising residue T59 in the SHP2 protein, optionally in one or more containers.
- the invention also relates to a kit for predicting the response of a subject suffering from non-small cell lung cancer (NSCLC) to an inhibitor of EGFR kinase, comprising means for determining the level of phosphorylation of at least one phosphorylation site, comprising residue T59 in the SHP2 protein, optionally in one or more containers.
- NSCLC non-small cell lung cancer
- the invention also relates to a kit for predicting an over-active EGFR of a subject suffering from a disease or disorder to an inhibitor of EGFR kinase, comprising means for determining the level of phosphorylation of at least one phosphorylation site, comprising residue T59 in the SHP2 protein, optionally in one or more containers.
- the invention also relates to a kit for predicting an over-active EGFR of a subject suffering from non-small cell lung cancer (NSCLC)to an inhibitor of EGFR kinase, comprising means for determining the level of phosphorylation of at least one phosphorylation site, comprising residue T59 in the SHP2 protein, optionally in one or more containers.
- NSCLC non-small cell lung cancer
- the invention also relates to a use of phosphorylated T59 on SHP2 as a marker that can predict the response of a subject having an over active-EGFR to an inhibitor of EGFR kinase activity.
- This use comprises determining amino acid residues in one or more proteins from the EGFR signaling pathway that are over- or under-phosphorylated, compared to a control level.
- the invention also relates to a use of phosphorylated T59 on SHP2 as a marker that can predict the response of a subject having an over active-EGFR to an inhibitor of EGFR kinase activity, comprising determining the phosphorylation of T59 on SHP2 in one or more proteins from the EGFR signaling pathway that are over- or underphosphorylated, compared to a control level.
- Another embodiment of the invention relates to a method for predicting, whether a patient suffering from non-small cell lung cancer (NSCLC) is suitable for anti-EGFR therapy, comprising the steps: a) collecting a sample from a tumor of a subject that having non-small cell lung cancer (NSCLC); b) determining the level of phosphorylation of at least one phosphorylation site, comprising residue T59 in the SHP2 protein; c) comparing the level of phosphorylation of the at least one phosphorylation site, comprising residue T59, to a control level; wherein a significantly elevated level of phosphorylation of at least one phosphorylation site, comprising residue T59, compared to the control level indicates that the subject is suitable for anti-EGFR therapy.
- NSCLC non-small cell lung cancer
- predicting the response of a subject suffering from a disease, in particular non-small cell lung cancer (NSCLC) can be replaced by the term “predicting, whether a patient is suitable for anti-EGFR therapy”, if nothing specific is defined.
- NSCLC non-small cell lung cancer
- Protein is used interchangeably with polypeptide, and includes protein fragments and domains as well as whole proteins.
- Phosphorylatable amino acid or phosphorylated means any amino acid that is capable of being modified by addition of a phosphate group, and includes both forms of such amino acid.
- Phosphorylatable peptide sequence means a peptide sequence comprising at least one phosphorylatable amino acid.
- the term “subject” refers to any human or animal.
- a (nonhuman) animal includes all vertebrates, e.g. mammals and non-mammals, including cows, sheep, pigs, goats, horses, poultry, dogs, cats, non-human primates, rodents etc.
- the subject is a human subject.
- Epidermal growth factor is a protein that stimulates cell growth and differentiation.
- the EGF-receptor binds to EGF and forms a protein-ligand interaction.
- a first embodiment of the invention is a method for prediction of the response of a subject suffering from a disease or disorder, in particular non-small cell lung cancer, to an inhibitor of EGFR kinase activity.
- a special embodiment of the invention is a method for predicting if a (human) patient suffering from a cancer that makes him a candidate for treatment with an inhibitor of EGFR kinase activity is responsive to a treatment with an inhibitor of the EGFR kinase activity, comprising the steps a) to c), as defined above and in the following, wherein phosphorylation of at least one phosphorylation site, comprising the residue T59 in the SHP2 protein, indicates that the patient is likely to be responsive to a treatment with an agent that inhibits the kinase activity of EGFR.
- step a) a sample from a tumor in a subject having a cancer of epithelial cell origin is collected.
- Suitable samples contain tissues or cells from the tumor of a subject having a cancer of epithelial cell origin.
- the sample preferably comprises a biopsy sample, such as a tumor biopsy, primary tissue, metastatic tissue.
- the specimen can be obtained by needle biopsy, image-guided biopsy, surgical (excisional) biopsy, shave/punch biopsy, endoscopic biopsy, laparoscopic biopsy and combinations thereof.
- the tumor sample can be obtained from the patient by routine measures known to the person skilled in the art, i.e., biopsy (taken by aspiration or punctuation, excision or by any other surgical method leading to biopsy or resected cellular material). In this way, it is possible to obtain tissue for the method of the present invention. However, the tumor will not be removed (completely) during collection of a sample. In the sense of the present invention, "collecting sample from a tumor” is not intended to be directed a therapeutic treatment method.
- the subject has an over-active EGFR.
- Over-activity of EGFR is not synonymous to over-expression of EGFR.
- Over-active of epidermal growth factor receptor (EGFR) is observed in many cancers, sometimes accompanied by gene amplification.
- over-active EGFR refers to an increase in EGFR-driven phosphorylation-activity, not in the EGFR expression itself.
- Samples are classified as EGFR over-active based on their somatic mutation profile.
- a sample is stated EGFR over-active if it carries at least one activating mutations as defined below.
- the over-active EGFR is caused by a mutation in EGFR or by a protein interaction with EGFR such that the mutation or the protein interaction causes the receptor to be conformationally altered and to become engaged in an active signaling state contributing to a disease condition.
- the over-active of EGFR is caused by a mutation in the EGFR gene.
- the EGFR gene is present on chromosome 7p11 .2 and has 28 exons coding for a transmembrane receptor protein of 464 amino acids.
- exons 5-7 and 13-16 code for the ligand binding domain
- exons 18-24 code for the tyrosine kinase domain and autophosphorylation occurs in the region encoded by exons 25-28.
- the mutation affects at least one of the afore-mentioned domains.
- EGFR mutations are in particular observed in exons 18-21.
- the EGFR mutation is especially selected from a mutation that alters L858, T790, G719, L861 , S768; a deletion in exon 19;
- the mutation includes:
- a second preferred embodiment the over-active EGFR is caused by a protein interaction with EGFR such that the receptor to be conformationally altered and to become engaged in an active signaling state contributing to a disease condition.
- the disease or disorder from which the subject is suffering is cancer, in particular cancer of epithelial cell origin.
- This cancer includes primary cancer and secondary (metastatic) disease.
- the cancer is selected from glioblastoma, melanoma, and lung, breast, ovary, prostrate, stomach, pancreas, bladder, head, neck, colon, colorectal and kidney cancer.
- Especially the disease or disorder is non-small cell lung cancer (NSCLC).
- NSCLC non-small cell lung cancer
- step b) of the method according to the invention the level of phosphorylation of the phosphorylation site residue T59 in the SHP2 protein, is determined.
- the level of phosphorylation can be determined by targeted mass spectrometric analysis on tumor tissue.
- the determination can be also done by development of an antibody and/or IHC assay specifically targeting the p-site.
- the antibodies for use in the invention may be produced by any suitable method known in the art. Such antibodies include, but are not limited to, polyclonal, monoclonal, humanized, phage display-derived antibodies or chimeric antibodies.
- step c) of the method according to the invention the level of phosphorylation of at least one phosphorylation site, comprising residue T59 in the SHP2 protein, is compared to a control level.
- a significantly elevated level of phosphorylation of at least one phosphorylation site, comprising residue T59, compared to the control level indicates that the subject is likely to be responsive to an agent that inhibits the kinase activity of EGFR.
- a significantly elevated level of phosphorylation of at least one phosphorylation site, comprising residue T59, compared to the control level indicates that the subject has an over-active EGFR.
- control level refers to the level of phosphorylation at a given amino acid residue of a protein, in particular on the amino acid side chain, in a non-cancerous tissue.
- control level refers to the level of phosphorylation at a given amino acid residue of a protein in a normal, non-tumorous tissue.
- a "significantly elevated" level of phosphorylation is a level whose difference from the control level is statistically significant, using statistical methods that are appropriate and well-known in the art.
- the phosphorylation of at least one phosphorylation site, comprising residue T59 of SHP2 in a subject having an over-active EGFR.
- Methods for measuring the level of phosphorylation at an amino acid residue are conventional and routine. In general, the measurement relies on the existence of sets of antibodies that are specific for either the non-phosphorylated or the phosphorylated forms of a particular amino acid residue of interest in the context of a protein of interest (such as EGFR). Such antibodies are commercially available or can be generated routinely, using conventional procedures.
- a synthetic peptide comprising an amino acid of interest from a protein of interest (either in the non-phosphorylated or phosphorylated form) is used as an antigen to prepare a suitable antibody.
- the antibody can be polyclonal or monoclonal. Antibodies are selected and verified to detect only the phosphorylated version of the protein but not the non-phosphorylated version of the native or denatured protein, and vice-versa.
- Such antibodies can be used in a variety of ways. For example, one can prepare whole cell lysates from patient samples and spot them in an array format onto a suitable substrate, such as nitrocellulose strips or glass slides. Preferably, the proteins in the samples are denatured before spotting. In general, the cells are spotted at serial dilutions, such as two-fold serial dilutions, to provide a wide dynamic range. Suitable controls, such as positive controls or controls for control levels, can be included. Each array is then probed with a suitable detectable antibody, as described above, to determine and/or to quantitate which amino acid residue(s) in the various proteins of interest are phosphorylated. Methods for immuno- quantitation are conventional.
- suitable assays employing such antibodies to assess the level and/or degree of phosphorylation at a residue of interest include, e.g., Western blots, ELISA assays, immunhistochemistry, mass spectroscopy, and other conventional assays.
- Suitable methods include those that can detect the phosphoprotein in a very small sample (e.g. about 200 cells). Alternatively, methods can be used that are suitable for a large sample size (e.g. FFPE tissue sections).
- Assays to measure the presence and/or level of phosphorylated residues can be readily adapted to high throughput formats, e.g. using robotics, if desired.
- the inventive method can further comprise determining the activation state of the EGFR.
- the presence or absence of an activating mutation can be determined in a patient sample.
- a subject having both an activating mutation and hyperphosphorylation at the SHP2 residues T59 can be determined in accordance with the present invention to be a responder, and thus selected for EGFR treatment.
- hyperproliferative conditions such as cancers, precancerous conditions, metabolic disorders (e.g., diabetes), skin disorders or diseases, cardiovascular disease, hyperproliferative cell diseases or disorders, psoriasis, obesity, inflammatory airway disease, asthma, COPD, and neurological disorders. Patients suffering from those conditions can also be assayed by a method of the invention.
- One aspect of the invention is a method for treating a subject suffering from a disease or disorder, in particular non-small cell lung cancer, having over-active EGFR, comprising the steps i) measuring the level of phosphorylation at SHP2 residue T59 in a sample from the subject and, if the levels of phosphorylation compared to a control level suggest that the subject is likely to be responsive to EGFR therapy, ii) administering EGFR treatment to the subject (administering an effective level of an EGFR inhibitor, such as an inhibitor of EGFR kinase activity).
- an EGFR inhibitor such as an inhibitor of EGFR kinase activity
- the EGFR inhibitor is selected from BIBX 1382; Cetuximab (Erbitux); CI-1033 (Canertinib); EKB-569; EMD 55900; EMD 72000; Erlotinib (OSI-774; Tarceva); Gefitinib (ZD1839; Iressa); GW-2016; hR3; ICR-62; Lapatinib (GW-572016); Lavendustin A;
- Tyrphostin 23 (RG-50810); Tyrphostin 25 (RG-50875); Tyrphostin 46; Tyrphostin 47 (RG- 50864, AG-213); Tyrphostin 51 ; ZD-6474; a derivative thereof, or a combination thereof.
- the subject is a human patient suffering from NSCLC
- the EGFR kinase inhibitor is selected from Iressa® (gefitinib), Tarceva® (erlotinib), Vizimpro® (dacomitinib), Gilotrif® (afatinib), or mixtures thereof.
- Combinations of these agents, with each other or with conventional agents, such as chemotherapeutic agents, can be used.
- compounds may be characterized as being "EGFR inhibitors,” “EGFR kinase inhibitors,” or “inhibitors of the EGFR pathway,” the present invention is not limited to the mechanism by which such agents achieve therapeutic efficacy.
- a patient subset selected in accordance with the present invention may respond to EGFR treatment, although the mechanism of action may not be related to, or completely related to, modulation of the EGFR pathway.
- a further aspect of the invention is the treatment of a patient identified as potential responder with a pharmaceutical composition comprising at least one inhibitor of EGFR kinase as defined above in an effective amount and a pharmaceutically acceptable carrier.
- Such a pharmaceutical composition can be administered to a subject having an overactive EGFR, wherein the subject is determined by a method according to the invention to be likely to be responsive to an EGFR kinase inhibitor.
- the inhibitors discussed herein can be formulated into various compositions, e.g., pharmaceutical compositions, for use in therapeutic treatment methods.
- the pharmaceutical compositions can be assembled as a kit.
- a pharmaceutical composition of the invention comprises an anticancer-effective amount of the inhibitor.
- An "anticancer effective amount,” as used herein, is an amount that is sufficient to effect at least a therapeutic response in the individual over a reasonable time frame. For example, it can ameliorate, at least to a detectable degree, the symptoms of a cancer, or can inhibit the growth of a tumor, etc.
- composition can comprise a carrier, such as a pharmaceutically acceptable carrier.
- a carrier such as a pharmaceutically acceptable carrier.
- pharmaceutically acceptable is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to a subject without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.
- the carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art.
- compositions suitable for oral, parenteral, aerosol, transdermal, topical, or other forms of administration will be evident to the skilled person.
- One skilled in the art can easily determine the appropriate dose, schedule, and method of administration for the exact formulation of the composition being used, in order to achieve the desired anti-cancer effective amount or effective concentration of the agent in the individual patient.
- One skilled in the art also can readily determine and use an appropriate indicator of the "effective concentration" of the compounds of the present invention by a direct or indirect analysis of appropriate patient samples (e.g., blood and/or tissues).
- an anticancer effective amount The dose of an inhibitory agent of the invention, or composition thereof, administered to an animal, particularly a human, should be sufficient to effect at least a therapeutic response in the individual over a reasonable time frame (an anticancer effective amount).
- the exact amount of the dose will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the severity or mechanism of any disorder being treated, the particular agent or vehicle used, its mode of administration and the like.
- the dose used to achieve a desired anticancer concentration in vivo will be determined by the potency of the particular inhibitory agent employed, the pharmacodynamics associated with the agent in the host, the severity of the disease state of infected individuals, as well as, in the case of systemic administration, the body weight and age of the individual.
- the size of the dose also will be determined by the existence of any adverse side effects that may accompany the particular inhibitory agent, or composition thereof, employed. It is generally desirable, whenever possible, to keep adverse side effects to a minimum.
- the inhibitors can be given at the same time, or the dosing can be staggered as desired.
- the two or more drugs can also can be combined in a composition. Doses of each can be less when used in combination than when either is used alone.
- a second embodiment of the invention a method for identifying over-active EGFR in subject, comprising the steps: i) collecting a sample from a tumor of a subject having a cancer of epithelial cell origin, in particular collecting a sample from a tumor of a subject having non-small cell lung cancer; ii) determining the level of phosphorylation of at least one phosphorylation site comprising residue T59 in the SHP2 protein; iii) comparing the level of phosphorylation of at least one phosphorylation site comprising residue T59 to a control level; wherein a significantly elevated level of phosphorylation of at least one phosphorylation site comprising residue T59 compared to the control level indicates that the subject has likely an over-active EGFR.
- a third embodiment of the invention is a kit for predicting the response of a subject suffering from a disease or disorder, in particular non-small cell lung cancer, to an inhibitor of EGFR kinase, comprising means for determining the level of phosphorylation of at least one phosphorylation site comprising residue T59 in the SHP2 protein, optionally in one or more containers.
- the kit can be useful for predicting the response of a subject suffering from a disease or disorder, in particular non-small cell lung cancer, caused by an over-active EGFR, in particular cancer of epithelial origin, comprising reagents and/or devices for measuring the level of phosphorylation of at least one phosphorylation site comprising residue T59.
- the kit may comprise reagents and/or devices for preparing a sample such as collecting a tissue and/or excising a sample from the tissue; for spotting test samples on a suitable surface, such as nitrocellulose strips or glass slides; for performing immunoquantitation such as labeled antibodies, or reagents for labeling antibodies; instructions for performing a method of the invention; etc.
- the components of the kit may, optionally, be packaged in one or more containers.
- kits according to the invention can be in experimental applications to identify a phosphorylation pattern that is predictive of the response of a subject to a therapeutic agent.
- a skilled person will recognize components of kits suitable for carrying out any of the methods of the invention.
- the kit according to the invention comprises suitable buffers; one or more containers or packaging material; and/or instructions for performing the method.
- the reagents of the kit may be in containers in which the reagents are stable, e.g. in lyophilized form or stabilized liquids.
- the reagents may also be in single use form, e.g., in single dosage form.
- Companion diagnostic tests & compounds to determine e.g., whether a mutation exists and is linked to a specific treatment can be found on the FDA database https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved- companion-diagnostic-devices-in-vitro-and-imaging-tools.
- a fourth embodiment of the invention is the use of T59 on SHP2 as a marker that can predict the response of a subject having an over active-EGFR to an inhibitor of EGFR kinase activity.
- This use comprises determining amino acid residues, in particular determining the phosphorylation of T59 on SHP2, in one or more proteins from the EGFR signaling pathway that are over- or under-phosphorylated, compared to a control level.
- Figure 1 shows EGFR mutation frequencies. EGFR-activity is influenced by specific genetic mutations. The somatic variations that are detected in tumor samples from patients can be utilized as primary indicator for increased EGFR kinase-activity. Figure 1 shows those 15 mutations that arise in at least two samples from a frequency counts of all 82 distinct mutations reported for EGFR throughout the samples in a NSCLC cohort.
- Figure 2 shows Iog2-transformed intensities for PTPN11 -T59. Based on the mutations presented in Figure 1 , it is possible to classify samples based on their EGFR activity. Samples that carry solely somatic EGFR mutations with increasing effects on kinase activity, it can be classified as “Activated EGFR”. Vice versa, samples that carry none or other mutations than EGFR-activating ones can be seen as “Wild-Type EGFR”. Based on this classification, we 435 Wild-Type EGFR samples and 54 activated EGFR samples were identified. When analyzing the Iog2 transformed intensities of PTN11-T59, a significant difference between both groups occurred.
- An example threshold of t > 16 shows that this phosphosite acts as suitable group separator.
- samples with activated EGFR commonly show PTN11 -T59 intensities of over 16, while Wild-Type EGFR is below this threshold.
- samples that carry multiple but only partially EGFR-activating mutations are classified as “Wild-Type EGFR” but also show high PTN11-T59 intensities above 16, which indicates that this method is able to find samples with activated EGFR, that might exceed the pure level of somatic mutation derived kinase-activity.
- FIG. 3 Ischemia time impact. This figure represents the sample Iog2-transformed intensities of PTN11 -T59 as Figure 2. The data is divided into ischemia time intervals of 5 minutes, i.e. intervals that describe the time that passed between tissue extraction and freezing. By this method it was possible to track if PTN11 -T59 is stable over time. The difference between samples with “Wild-Type EGFR” and “Activated EGFR” stays intact over the complete time periods and none of the groups shows a notable downwards trend with increasing time.
- PTN11-T59 biomarker according to the invention for EGFR kinase activity can be seen as threshold based binary classification where high scores are associated with elevated kinase activity.
- samples with overactivated EGFR kinase activity should be enriched among the highest phosphorylation measurements.
- the better this enrichment the higher the area under the curve (AUC) of the corresponding receiver operating characteristic (ROC) curve.
- AUC area under the curve
- ROC receiver operating characteristic
- the curve reflects the concordance of EGFR overactive samples as defined by genetic mutations, and those samples with a high phosphorylation signal (seen here as true positive rate TPR).
- the false positive rate here reflects the presence of EGFR wild-type samples for which a high phosphorylation signal is observed. The latter could indicate biological EGFR activating processes independent of the genetic mutation state of EGFR.
- figure 4 shows that p-sites of ERBB3 (ERBB3-*) and ERK1 and ERK2 (ERK1/2-*) have a low predictive power compared to the pure PTN11-T59 model according to the invention.
- the method to predict elevated EGFR kinase activity according to the present invention relies on a p-site-specific measurement. Hence, general protein phosphorylation is not a sufficient source of information.
- PR precision-recall
- the graphic is constructed analogous to the ROC curve, but here one compares the precision (positive predictive value, PPV), the fraction of genetically defined EGFR-overactivated samples relative to the total number of samples predicted to be EGFR-overactivated using the current invention (on the y-axis) with the recall, which is equivalent to the true positive rate (TPR on the x-axis).
- PR precision-recall
- Figure 6 A graphical representation of markers that could be useful in EGFR therapy.
- patients who appear suitable for EGFR therapy are defined from all NSCLC patients. This is currently done using mutations in EGFR.
- a single phosphosite on PTN11 is used to define the over activation of the EGFR.
- Zhang et aL, 2021 lists attempts to identify markers for none- responders from lung cell lines, and uses on EGFR mutations to define activity of the EGFR.
- Li et aL, 2014 defines a negative selection criteria response to therapy. Both approaches are a negative selection criterion that has nothing to do with EGFR activity per se.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne un procédé pour sélectionner des patients qui peuvent répondre à un traitement par des inhibiteurs de tyrosine kinase (TKI). L'invention concerne en outre un kit de diagnostic pour la prédiction d'une réponse à un inhibiteur de l'activité de la kinase EGFR. De plus, l'invention concerne l'utilisation de T59 phosphorylé sur la SHP2 en tant que biomarqueur pour prédire l'activité de la kinase EGFR.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22192093 | 2022-08-25 | ||
EP22192093.7 | 2022-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024042077A1 true WO2024042077A1 (fr) | 2024-02-29 |
Family
ID=83689191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/073029 WO2024042077A1 (fr) | 2022-08-25 | 2023-08-22 | Procédé de prédiction de la réponse à un inhibiteur de l'activité de la kinase egfr |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024042077A1 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007027916A2 (fr) | 2005-08-31 | 2007-03-08 | Cell Signaling Technology, Inc. | Reactifs de detection de la phosphorylation proteinique dans la voie de signalisation de carcinome |
WO2007106432A2 (fr) | 2006-03-10 | 2007-09-20 | George Mason Intellectual Properties, Inc. | Statut du recepteur de l'egf pour le traitement des maladies |
-
2023
- 2023-08-22 WO PCT/EP2023/073029 patent/WO2024042077A1/fr unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007027916A2 (fr) | 2005-08-31 | 2007-03-08 | Cell Signaling Technology, Inc. | Reactifs de detection de la phosphorylation proteinique dans la voie de signalisation de carcinome |
WO2007106432A2 (fr) | 2006-03-10 | 2007-09-20 | George Mason Intellectual Properties, Inc. | Statut du recepteur de l'egf pour le traitement des maladies |
Non-Patent Citations (9)
Title |
---|
GRIMES ET AL., SCIENCE SIGNALING, vol. 11, no. 531, 2018 |
GRIMES MARK ET AL: "Integration of protein phosphorylation, acetylation, and methylation data sets to outline lung cancer signaling networks", vol. 11, no. 531, 22 May 2018 (2018-05-22), US, XP093021590, ISSN: 1945-0877, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822907/pdf/nihms-1055455.pdf> DOI: 10.1126/scisignal.aaq1087 * |
J. BIOL. CHEM., vol. 270, no. 36, 1995, pages 21277 - 21284 |
LI ET AL., ONCOLOGY REPORTS, vol. 33, no. 2, 2014, pages 951 - 957 |
LI JIXIA ET AL: "Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells", ONCOLOGY REPORTS, vol. 33, no. 2, 2 December 2014 (2014-12-02), pages 951 - 957, XP055954955, ISSN: 1021-335X, DOI: 10.3892/or.2014.3639 * |
TAUTZ LUTZ ET AL: "Protein Tyrosine Phosphatases: Structure, Function, and Implication in Human Disease", vol. 1053, 2013, Totowa, NJ, pages 179 - 221, XP093021660, ISSN: 1064-3745, ISBN: 978-1-62703-562-0, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158066/pdf/nihms-1698850.pdf> DOI: 10.1007/978-1-62703-562-0_13 * |
Z.SONG, ACTA PHARMACEUTICA SINICA B, vol. 11, no. 1, 2021, pages 13 - 29 |
ZHANG ET AL., CANCER RESEARCH, vol. 81, no. 11, 2021, pages 3051 - 3066 |
ZHANG XU ET AL: "Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance", vol. 81, no. 11, 1 June 2021 (2021-06-01), US, pages 3051 - 3066, XP093021072, ISSN: 0008-5472, Retrieved from the Internet <URL:https://aacrjournals.org/cancerres/article-pdf/81/11/3051/3085178/3051.pdf> DOI: 10.1158/0008-5472.CAN-20-2435 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8093011B2 (en) | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors | |
US8383357B2 (en) | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors | |
CN111337678A (zh) | 与肿瘤免疫治疗效果相关的生物标志物及其应用 | |
WO2012088337A1 (fr) | Sélection de médicament pour traitement de cancer à l'aide de réseaux à base d'anticorps | |
WO2007106432A2 (fr) | Statut du recepteur de l'egf pour le traitement des maladies | |
US20240084037A1 (en) | Protein biomarker and uses thereof | |
AU2016270686B2 (en) | Quantifying Her2 protein for optimal cancer therapy | |
JP6383787B2 (ja) | 卵巣癌の治療方法 | |
WO2016168440A1 (fr) | Procédés de traitement du cancer du poumon | |
Radhakrishnan et al. | Inhibition of rapamycin-induced AKT activation elicits differential antitumor response in head and neck cancers | |
EP2745113B1 (fr) | Marqueurs de susceptibilité d'un inhibiteur de kinase de famille de src | |
KR101928618B1 (ko) | Tk1 단백질의 발현이 항진된 결장직장암 환자에 대한 치료효과 예측 방법 | |
WO2024042077A1 (fr) | Procédé de prédiction de la réponse à un inhibiteur de l'activité de la kinase egfr | |
KR20180013878A (ko) | 렌바티닙 및 에베로리무스를 포함하는 병용 요법을 위한 생체표지 | |
TW202417641A (zh) | 預測對egfr激酶活性之抑制劑的反應之方法 | |
CA2762025A1 (fr) | Procede de prediction de la faculte de reponse therapeutique d'un patient a un traitement medical impliquant un inhibiteur de l'egfr | |
Radwan-Oczko et al. | Comparison of biomarker expression in oral lichen planus and oral lichenoid lesions | |
JP5321780B2 (ja) | 肺癌の治療方法 | |
US20110269139A1 (en) | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators | |
JP2022502662A (ja) | レンバチニブ及びエベロリムスを含む併用療法のためのバイオマーカー | |
US20230365690A1 (en) | Methods of treating malignant glioblastoma | |
EP2702409B1 (fr) | Utilisation de CXCR1 pour prévoir la réponse à un traitement avec agent thérapeutique ciblant le récepteur du facteur de croissance épidermique | |
WO2022159569A1 (fr) | Phénotype sanguin périphérique lié à des résultats après traitement d'immunothérapie | |
EP4025704A1 (fr) | Signatures d'activité kinase pour prédire la réponse de patients atteints d'un carcinome pulmonaire non à petites cellules à un inhibiteur de point de contrôle immunitaire pd-1 ou pd-l1 | |
CA2987610A1 (fr) | Quantification de la proteine her2 pour une therapie anticancereuse optimale |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23757946 Country of ref document: EP Kind code of ref document: A1 |